Strategy for prevention of cancers of the esophagus

Ann N Y Acad Sci. 2014 Sep;1325:108-26. doi: 10.1111/nyas.12529.

Abstract

The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the animal reflux-inflammation models for Barrett's esophagus and esophageal adenocarcinoma; genomic/epigenomic analyses; eflornithine-based combinations; the molecular derangements that promote neoplastic transformation; the role of COX-2 inhibitors, proton pump inhibitors, and phase II trials in Barrett's adenocarcinoma; statins in chemoprevention and treatment of esophageal cancer; and biomarkers as potential targets in Barrett's adenocarcinoma.

Keywords: Barrett's adenocarcinoma; COXIBs, PPIs; OESO; animal reflux-inflammation models; biomarkers; elofrnithine; statins.

Publication types

  • Congress

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Barrett Esophagus / diagnosis
  • Barrett Esophagus / metabolism
  • Barrett Esophagus / prevention & control
  • Biomarkers, Tumor / metabolism
  • Cell Transformation, Neoplastic / metabolism
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Eflornithine / therapeutic use
  • Esophageal Neoplasms / diagnosis*
  • Esophageal Neoplasms / metabolism
  • Esophageal Neoplasms / prevention & control*
  • Gastroesophageal Reflux / diagnosis
  • Gastroesophageal Reflux / metabolism
  • Gastroesophageal Reflux / prevention & control
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Paris
  • Proton Pump Inhibitors / therapeutic use

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Cyclooxygenase 2 Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Proton Pump Inhibitors
  • Eflornithine